Prosecution Insights
Last updated: April 19, 2026

Actinium Pharmaceuticals Inc.

11 pending office actions

Portfolio Summary

11
Total Pending OAs
5
Final Rejections
6
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18632379 HUMANIZED ANTI-CD45 ANTIBODIES CHASE, CAROL ANN 1646 Final Rejection Apr 11, 2024
18323276 CALRETICULIN NANOBODIES SUNSHINE, HANNAH LOUISE 1647 Non-Final OA May 24, 2023
18146149 HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS LOCKARD, JON MCCLELLAND 1647 Non-Final OA Dec 23, 2022
17726296 COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER ROGERS, JAMES WILLIAM 1618 Final Rejection Apr 21, 2022
17702648 COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER CUNNINGCHEN, KATHLEEN MARY 1646 Non-Final OA Mar 23, 2022
17532919 HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS LOCKARD, JON MCCLELLAND 1647 Non-Final OA Nov 22, 2021
17606254 COMPOSITIONS AND METHODS OF IMMUNODEPLETION FOR THE TREATMENT OF MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISEASES JONES, DAMERON LEVEST 1618 Final Rejection Oct 25, 2021
16954105 COMBINATION IMMUNOTHERAPY AND CHEMOTHERAPY FOR THE TREATMENT OF A HEMATOLOGICAL MALIGNANCY WELLS, LAUREN QUINLAN 1622 Non-Final OA Jun 15, 2020
16755590 ANTI-CD45-BASED LYMPHODEPLETION METHODS AND USES THEREOF IN CONJUNCTION WITH ACT-BASED CANCER THERAPIES JOHANSEN, PETER N. 1644 Final Rejection Apr 12, 2020
16755589 COMBINATION THERAPY FOR TREATMENT OF A HEMATOLOGICAL DISEASE BUTTICE, AUDREY L 1647 Final Rejection Apr 12, 2020
16627872 TREATMENTS FOR A HEMATOLOGICAL MALIGNANCY SAMALA, JAGADISHWAR RAO 1618 Non-Final OA Dec 31, 2019

Managing Actinium Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month